期刊
RADIOTHERAPY AND ONCOLOGY
卷 92, 期 2, 页码 260-265出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.radonc.2008.12.012
关键词
Esophageal cancer; A randomized phase II study; Chemoradiotherapy
资金
- Japanese Radiation Oncology Study Group
- Ministry of Education, Science, Sports, and Culture, Japan [18209040]
- Grants-in-Aid for Scientific Research [18209040] Funding Source: KAKEN
Purpose: A randomized phase II study was conducted to compare the toxicity and efficacy of combining short-term chemotherapy (CT) or protracted CT with radiotherapy (RT) for esophageal cancer. Materials and methods: Eligible patients were <75 years and with performance status (PS) of 0-2, and had stages II-IVA esophageal cancer. Two cycles of cisplatin 70 mg/m(2) for 1 day and 5FU 700 mg/m(2) for 5 days (arm A) or cisplatin 7 mg/m(2) for 10 days and 5FU 250 mg/m(2) for 14 days (arm B) were given with RT of 60 Gy/30 fractions/7 weeks (1-week split). Results: Of 91 patients enrolled, 46 were randomized to arm A and 45 to arm B. Two cycles of CT were given concurrently with RT for 89% in arm A and for 71% in arm B with significant difference (P = .031). The 2- and 5-year overall survival rates for arm A were 46% and 35%, while those for arm B were 44% and 24%, respectively, without significant difference. The 2- and 5-year progression-free survival rates for arm A were 30% and 30%, while those for arm B were 29% and 12%, respectively. Conclusions: Protracted infusion CT with RT provides no advantage over standard short-term infusion CT with RT for esophageal cancer. (C) 2009 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 92 (2009) 260-265
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据